<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dexlansoprazole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dexlansoprazole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dexlansoprazole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12160" href="/d/html/12160.html" rel="external">see "Dexlansoprazole: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="130777" href="/d/html/130777.html" rel="external">see "Dexlansoprazole: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6884085"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dexilant</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397503"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dexilant</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F6892890"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Proton Pump Inhibitor;</li>
<li>
                        Substituted Benzimidazole</li></ul></div>
<div class="block doa drugH1Div" id="F6892955"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Doses &gt;30 mg do not provide additional benefit during maintenance phase.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7eb41f5-ab77-43d2-b32d-436b6b436e7f">Eosinophilic esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic esophagitis (off-label use): Oral:</b> 30 mg once daily for an 8-week trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bonis.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bonis.1','lexi-content-ref-Manu.1'])">Ref</a></span>). Some experts increase to 60 mg once daily after 4 weeks if symptoms fail to improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bonis.1','lexi-content-ref-26958557','lexi-content-ref-26228516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bonis.1','lexi-content-ref-26958557','lexi-content-ref-26228516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af13b8bc-31d9-4d53-ade6-d0f129e2f0f1">Gastroesophageal reflux disease, erosive or nonerosive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive: Note: </b>For patients with alarm symptoms (eg, dysphagia), referral to a specialist is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34807007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34807007'])">Ref</a></span>). Maximal acid suppression is generally observed after ~3 days of continuous therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23350044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23350044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial therapy:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Mild and intermittent symptoms (&lt;2 episodes/week) without erosive esophagitis or Barrett esophagus:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts reserve proton pump inhibitors (PPIs) as alternatives to H<sub>2</sub>-receptor antagonists (H<sub>2</sub>RAs) for patients who have residual acid reflux symptoms despite twice-daily H<sub>2</sub>RA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 30 mg once daily for 4 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34807007','lexi-content-ref-31597230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34807007','lexi-content-ref-31597230'])">Ref</a></span>). <b>Note: </b>Some experts continue therapy until asymptomatic for 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Severe or frequent symptoms (≥2 episodes/week) without erosive esophagitis or Barrett esophagus: </i>Oral:</b> 30 mg once daily for 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34807007','lexi-content-ref-19248200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34807007','lexi-content-ref-19248200'])">Ref</a></span>). <b>Note: </b>Some experts continue therapy until patient has been asymptomatic for 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Erosive esophagitis or Barrett esophagus</i></b>: <b>Oral:</b> 60 mg once daily for 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>) then 30 mg once daily indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35354777','lexi-content-ref-35183361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35354777','lexi-content-ref-35183361'])">Ref</a></span>), <b>or </b>30 mg once daily indefinitely (preferred by some experts) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Residual symptoms despite 30 mg once daily:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Referral to a specialist is recommended<b>. </b>Options include doubling the PPI dose, switching to a different PPI, or adding an H<sub>2</sub>RA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32691466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32691466'])">Ref</a></span>). For patients requiring concomitant H<sub>2</sub>RA therapy, some experts administer the H<sub>2</sub>RA at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fass.2019','lexi-content-ref-19821323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fass.2019','lexi-content-ref-19821323'])">Ref</a></span>); however, others advocate concurrent administration to ensure adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26621819','lexi-content-ref-17505990','lexi-content-ref-17112810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26621819','lexi-content-ref-17505990','lexi-content-ref-17112810'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Recurrent symptoms after discontinuing acid suppression:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Recurrent symptoms after ≥3 months:</i> Repeat an 8-week course at the previously effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Recurrent symptoms after &lt;3 months:</i> Long-term maintenance at the lowest effective dose; referral to a specialist is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34807007','lexi-content-ref-Kahrilas.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34807007','lexi-content-ref-Kahrilas.2021'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b> If a dose is missed, administer as soon as possible; however, if the next scheduled dose is due, take the next dose on time and do not take the missed dose (do not take 2 doses at one time to make up for a missed dose).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b>
<b>Oral:</b> In patients who have received continuous therapy for &gt;6 months, some experts gradually taper therapy until discontinuation to avoid worsening or rebound symptoms. There is no single agreed upon discontinuation strategy. Some experts decrease the dose by 50% every week. Once patients are on the lowest dose for 1 week, discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wolfe.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wolfe.1'])">Ref</a></span>). An alternative strategy is to decrease the dose by 50% over 2 to 4 weeks, then discontinue. If the patient is already on the lowest possible dose, alternate day therapy may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29767318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29767318'])">Ref</a></span>). In addition, as-needed therapy with an H<sub>2</sub>RA or an antacid can be used during the taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25192903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25192903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991230"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, the pharmacokinetics of dexlansoprazole are not expected to be altered in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dexlansoprazole is not expected to be removed by hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50988459"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): 30 mg once daily is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F6892956"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Avoid use for &gt;8 weeks unless given for high-risk patients (eg, oral corticosteroid or chronic nonsteroidal anti-inflammatory drug use), patients with erosive esophagitis, Barrett esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sub>2</sub> blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F46944481"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="130777" href="/d/html/130777.html" rel="external">see "Dexlansoprazole: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce47ce73-fbfd-4c54-81d2-f67675bc530e">Erosive esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Healing:</i> Children ≥12 years and Adolescents: Oral: 60 mg once daily for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance of healing:</i> Children ≥12 years and Adolescents: Oral: 30 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5e4b52c-2ae7-4d5e-bc41-9d176e2d94e2">Gastroesophageal reflux disease, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease (GERD), symptomatic:</b>
<b>Note:</b> Guidelines recommend a 4- to 8-week treatment course; if improvement seen after 4 to 8 weeks, consider possible wean; if no response after 4 to 8 weeks, reevaluate diagnosis and consider referral to pediatric GI specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 30 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Oral: Based on experience in adults, some experts recommend a step-down approach in order to avoid worsening or rebound symptoms. One recommendation is to decrease the dose by 50% over 2 to 4 weeks. If the patient is already on the lowest possible dose, alternate day therapy may be considered. If symptoms worsen during treatment or after discontinuation, patient should be reevaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29767318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29767318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108887"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, the pharmacokinetics of dexlansoprazole are not expected to be altered in patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dexlansoprazole is not expected to be removed by hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51108888"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment:</p>
<p style="text-indent:-2em;margin-left:6em;">Healing of erosive esophagitis: Oral: 30 mg once daily for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Gastroesophageal reflux disease or erosive esophagitis maintenance: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended.</p></div>
<div class="block adr drugH1Div" id="F6892915"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence reported for adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (&lt;2%), angina pectoris (&lt;2%), bradycardia (&lt;2%), cardiac arrhythmia (&lt;2%), chest pain (&lt;2%), deep vein thrombosis (&lt;2%), edema (&lt;2%; including oral, facial edema, and pharyngeal edema), hypertension (&lt;2%), palpitations (&lt;2%), tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (&lt;2%), dermatitis (&lt;2%), erythema of skin (&lt;2%), pruritus (&lt;2%), skin lesion (&lt;2%), skin rash (&lt;2%), sunburn (&lt;2%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido (&lt;2%), goiter (&lt;2%), heavy menstrual bleeding (&lt;2%), hot flash (&lt;2%), hypercalcemia (&lt;2%), hypokalemia (&lt;2%), increased serum glucose (&lt;2%), increased serum potassium (&lt;2%), increased serum total protein (&lt;2%), menstrual disease (&lt;2%), weight gain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (&lt;2%), abdominal pain (adolescents: ≥5%), abdominal tenderness (&lt;2%), abnormal bowel sounds (&lt;2%), abnormal stools (&lt;2%), anorectal pain (&lt;2%), Barrett esophagus (&lt;2%), bezoar formation (&lt;2%), biliary colic (&lt;2%), change in appetite (&lt;2%), cholelithiasis (&lt;2%), colitis (microscopic; &lt;2%), colonic polyp (&lt;2%), constipation (&lt;2%), delayed gastric emptying (&lt;2%), diarrhea (adolescents and adults: ≥5%), duodenitis (&lt;2%), dysgeusia (&lt;2%), dyspepsia (&lt;2%), dysphagia (&lt;2%), enteritis (&lt;2%), eructation (&lt;2%), esophagitis (&lt;2%), flatulence (1% to 3%), gastric polyp (&lt;2%; including fundic gland), gastritis (&lt;2%), gastroenteritis (&lt;2%), gastroesophageal reflux disease (&lt;2%), gastrointestinal disease (&lt;2%), gastrointestinal hypermotility (&lt;2%), gastrointestinal perforation (&lt;2%), gastrointestinal ulcer (&lt;2%), halitosis (&lt;2%), hematemesis (&lt;2%), hematochezia (&lt;2%), hemorrhoids (&lt;2%), hiccups (&lt;2%), increased gastrin (&lt;2%), irritable bowel syndrome (&lt;2%), mucosal swelling (&lt;2%), mucus stools (&lt;2%), oral bullae (&lt;2%), oral herpes simplex infection (&lt;2%), oral paresthesia (&lt;2%), painful defecation (&lt;2%), proctitis (&lt;2%), rectal hemorrhage (&lt;2%), retching (&lt;2%), sore throat (&lt;2%), vomiting (1% to 2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (&lt;2%), dyspareunia (&lt;2%), dysuria (&lt;2%), urinary urgency (&lt;2%), vulvovaginal infection (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), decreased platelet count (&lt;2%), lymphadenopathy (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Decreased serum bilirubin (&lt;2%), hepatomegaly (&lt;2%), increased serum alanine aminotransferase (&lt;2%), increased serum alkaline phosphatase (&lt;2%), increased serum aspartate aminotransferase (&lt;2%), increased serum bilirubin (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (&lt;2%), influenza (&lt;2%), viral infection (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (&lt;2%), anxiety (&lt;2%), asthenia (&lt;2%), chills (&lt;2%), depression (&lt;2%), dizziness (&lt;2%), falling (&lt;2%), feeling abnormal (&lt;2%), headache (adolescents: ≥5%; adults: &lt;2%), insomnia (&lt;2%), memory impairment (&lt;2%), migraine (&lt;2%), pain (&lt;2%), paresthesia (&lt;2%), procedural pain (&lt;2%), psychomotor agitation (&lt;2%), seizure (&lt;2%), tremor (&lt;2%), trigeminal neuralgia (&lt;2%), vertigo (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), arthritis (&lt;2%), bone fracture (&lt;2%), joint sprain (&lt;2%), muscle cramps (&lt;2%), musculoskeletal pain (&lt;2%), myalgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation (&lt;2%), swelling of eye (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (&lt;2%), tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (&lt;2%), bronchitis (&lt;2%), cough (&lt;2%), dyspnea (&lt;2%), hyperventilation (&lt;2%), nasopharyngitis (adolescents: ≥5%; adults: &lt;2%), oropharyngeal pain (adolescents: ≥5%), pharyngitis (&lt;2%), pulmonary aspiration (&lt;2%), respiratory congestion (&lt;2%), sinusitis (&lt;2%), upper respiratory tract infection (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;2%), inflammation (&lt;2%), nodule (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia, hypomagnesemia, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile-</i>associated diarrhea, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Autoimmune hemolytic anemia, immune thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, drug reaction with eosinophilia and systemic symptoms, hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, chronic renal failure (Lazarus 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Constriction of the pharynx</p></div>
<div class="block coi drugH1Div" id="F6892897"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria) to dexlansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F6892898"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinoma: No occurrences of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia (such as those seen in studies of rodents exposed to lansoprazole) have been reported in humans.</p>
<p style="text-indent:-2em;margin-left:4em;">• <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young adults up to elderly patients. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of dexlansoprazole.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe cutaneous adverse reactions, including acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with PPI therapy. Patients on high-dose (multiple daily doses) or long-term therapy (≥1 year) should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fundic gland polyps: Use of PPIs increases risk of fundic gland polyps, especially with long term use (&gt;1 year). May occur without symptoms but nausea, vomiting, or abdominal pain may occur; GI bleeding and/or anemia may occur with ulcerated polyps. Diagnosis of polyps may also increase risk for small intestinal blockage. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypomagnesemia: Reported rarely, usually with prolonged PPI use of ≥3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Hypomagnesemia may lead to or exacerbate hypocalcemia in patients at risk (eg, hypoparathyroidism). Hypomagnesemia may also lead to hypokalemia. Hypomagnesemia and hypocalcemia may be corrected by magnesium/calcium supplementation, although discontinuation of dexlansoprazole may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tubulointerstitial nephritis: Acute tubulointerstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy. Patients may present with symptomatic hypersensitivity reaction to nonspecific symptoms of impaired renal function (eg, anorexia, malaise, nausea); may be diagnosed with biopsy and in the absence of extra-renal manifestations (eg, fever, rash, arthralgia). Discontinue and evaluate patients if acute tubulointerstitial nephritis is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> deficiency: Prolonged treatment (≥2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal infection (eg, <i>Salmonella, Campylobacter</i>): Use of PPIs may increase risk of these infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Patients with moderate hepatic impairment (Child-Pugh class B) may require dosage reductions; use is not recommended in patients with severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). Although lansoprazole exhibits the most potent CYP2C19 inhibition in vitro (Li 2004; Ogilvie 2011), an in vivo study of extensive CYP2C19 metabolizers showed less reduction of the active metabolite of clopidogrel when administered with lansoprazole/dexlansoprazole compared to esomeprazole/omeprazole (Frelinger 2012). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010; Levine 2011). The manufacturer of dexlansoprazole states that no dosage adjustment is necessary for clopidogrel when used concurrently with approved doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop dexlansoprazole treatment at least 14 days before CgA test; if CgA level is high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F55481034"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Dexlansoprazole is the R-enantiomer of lansoprazole. Neonatal and infant animal models (rat) have shown mitral valve heart thickening with lansoprazole treatment in 2 nonclinical, oral toxicity studies. Heart valve thickening occurred at doses resulting in 2.5 and 1.8 times the expected dexlansoprazole exposure in children 1 to 2 years of age; duration of treatment associated with valve thickening ranged from 5 days to 8 weeks. Valve thickening reversed or trended towards reversibility 4 weeks after discontinuation. The risk of heart valve thickening does not appear to occur at ≥2 years of age.</p>
<p style="text-indent:0em;margin-top:2em;">Gastric acid suppression medications have been associated with an increase in <i>Clostridioides</i>
<i>difficile</i> infection (CDI) and recurrent CDI in pediatric patients (Nylund 2014). In a retrospective, observational, case control study of pediatric patients 1 to 18 years of age who were hospitalized for diarrhea and abdominal pain, the use of proton pump inhibitors (PPIs) was significantly higher in patients who tested positive for <i>C. difficile</i> compared to patients who tested negative for <i>C. difficile</i> (22.1% vs 5.9%) (Turco 2010). Consider CDI diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>
<p style="text-indent:0em;margin-top:2em;">A large retrospective cohort study reviewed records for patients with a low baseline risk for fractures who were initiated on acid suppression therapy in the first year of life and evaluated the fracture risk in the first 5 years of life; a total of 97,286 patients were prescribed acid suppression therapy; 73% were prescribed H<sub>2</sub> blockers, 9% were prescribed PPIs, and 18% were prescribed both. H<sub>2 </sub>blocker use alone was not associated with an increased fracture hazard; however, PPI use was associated with a 21% increase and use of PPI plus H<sub>2</sub> blocker was associated with a 30% increase. Longer duration of therapy and earlier age at initiation seemed to also increase the fracture hazard. Study findings do not establish a causal relationship between PPI use and fractures. If acid suppression therapy is necessary in the first year of life, limiting therapy to a single drug and limiting the duration should be considered (Malchodi 2019). A second large cohort study reviewed records for 115,933 children &lt;18 years initiated on a PPI. PPI initiation was associated with a statistically significant 11% relative increase in risk of any fracture in patients ≥6 years. The increased risk also seemed to be more pronounced with a longer cumulative duration of PPI use (Wang 2020).</p></div>
<div class="block foc drugH1Div" id="F6892969"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dexilant: 30 mg, 60 mg [contains carrageenan, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg</p></div>
<div class="block geq drugH1Div" id="F6892888"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16321921"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Dexilant Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $12.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $12.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Dexlansoprazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $10.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $10.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397504"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dexilant: 30 mg, 60 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block adm drugH1Div" id="F6892966"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Administer without regard to meals; capsules should be swallowed whole; do not chew. Alternatively, patients who are unable to swallow capsules may open the capsule, sprinkle the intact granules onto 1 tablespoon of applesauce, and swallow intact granules immediately (do not chew granules). Do not save applesauce and granule mixture for later use. Capsules may also be opened for administration via NG tube or oral syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">NG tube (≥16 French): Open capsules and mix granules (not crushed) with 20 mL of water. Withdraw entire mixture into catheter-tip syringe; swirl syringe gently to prevent granules from settling and administer mixture immediately through NG tube (≥16 French) into the stomach. Refill syringe with 10 mL of water, swirl gently, and flush NG tube; repeat (with a second rinse). Do not save water and granule mixture for later use.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral syringe: Open capsules and mix granules (not crushed) with 20 mL of water. Withdraw entire mixture into oral syringe; swirl syringe gently to prevent granules from settling and administer mixture immediately into the mouth. Refill syringe with 10 mL of water, swirl gently, and administer; repeat (with a second rinse). Do not save water and granule mixture for later use.</p></div>
<div class="block admp drugH1Div" id="F52620277"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals; capsules should be swallowed whole; do not chew. For patients with difficulty swallowing capsules, capsules may be opened and the intact granules sprinkled on 1 tablespoon of applesauce; the mixture should be swallowed immediately; do not chew granules. Do not save applesauce and granule mixture for later use.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral syringe: Open capsules and mix granules (not crushed) with 20 mL of water. Withdraw entire mixture into oral syringe; swirl syringe gently to prevent granules from settling and administer mixture immediately into the mouth. Refill syringe with 10 mL of water, swirl gently, and administer; fill syringe with an additional 10 mL of water, swirl gently, and administer. Do not save water and granule mixture for later use.</p>
<p style="text-indent:-2em;margin-left:2em;">NG tube (≥16 French) administration: Open capsules and mix granules (not crushed) with 20 mL of water. Withdraw entire mixture into catheter-tip syringe; swirl syringe gently to prevent granules from settling and administer mixture immediately through NG tube into the stomach. Refill syringe with 10 mL of water, swirl gently, and flush NG tube; fill syringe with an additional 10 mL of water, swirl gently, and administer. Do not save water and granule mixture for later use.</p></div>
<div class="block meg drugH1Div" id="F15241699"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022287s037lbl.pdf%23page%3D24&amp;token=FwGVTp%2B6n1Lt1WgeRhCPY4JKLWAVQObnKwIaXI4X6PxpSqsTXcnaFhi76K0quh0T7arnpO3QICaXVIjwroXK4kbDirSztRRWeSeycZHMB2t68cMDtw5QdEER7Hf8YpuU&amp;TOPIC_ID=9074" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022287s037lbl.pdf#page=24</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F6892892"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Erosive esophagitis:</b> Healing of all grades of erosive esophagitis in patients ≥12 years of age for up to 8 weeks; to maintain healing of erosive esophagitis and relief of heartburn for up to 6 months in adults and 16 weeks in patients 12 to 17 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Symptomatic and nonerosive:</b> Treatment of heartburn associated with symptomatic nonerosive gastroesophageal reflux disease in patients ≥12 years of age for 4 weeks.</p></div>
<div class="block off-label drugH1Div" id="F50553799"><span class="drugH1">Use: Off-Label: Adult</span><p>Eosinophilic esophagitis</p></div>
<div class="block mst drugH1Div" id="F6892886"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dexlansoprazole may be confused with aripiprazole, lansoprazole</p>
<p style="text-indent:-2em;margin-left:4em;">Dexilant may be confused with DULoxetine</p>
<p style="text-indent:-2em;margin-left:4em;">Kapidex [DSC] may be confused with Capex, Casodex, Kadian</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Kapidex [DSC] may be confused with Capadex which is a brand name for propoxyphene/acetaminophen combination product [Australia, New Zealand]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Dexlansoprazole is identified in the Beers Criteria as a potentially inappropriate medication to be avoided (as scheduled use for &gt;8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection, pneumonia, GI malignancies, and bone loss/fractures <i>unless</i> given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett’s esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sub>2</sub> blockers) (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F7278224"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F7278223"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Acalabrutinib. This interaction is only applicable to acalabrutinib capsules. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May decrease the serum concentration of Dexlansoprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Atazanavir.  Management: Avoid use in treatment-experienced patients. In treatment-naive patients, administer boosted atazanavir 12 hours after the PPI and the PPI dose should not exceed the equivalent of 20 mg omeprazole. Monitor for reduced atazanavir efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with inhibitors of the proton pump (PPIs and PCABs).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors and potassium-competitive acid blockers, such as short-acting antacids or histamine-2 receptor antagonists. Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May decrease the serum concentration of Dexlansoprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Dexlansoprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of Dexlansoprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dacomitinib.  Management: Avoid concurrent use of dacomitinib with PPIs and PCABs. Antacids may be used. Histamine H2-receptor antagonists (HR2A) may be used if dacomitinib is given at least 6 hours before or 10 hours after the H2RA.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of PPIs or PCABs if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with PPIs or PCABs should be avoided in patients treated with delavirdine. The clinical significance of short-term PPI or PCAB therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextroamphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the bioavailability of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Gefitinib.  Management: Avoid use of inhibitors of the proton pump (PPIs or PCABs) with gefitinib when possible. If required, administer gefitinib 12 hours after the PPI/PCAB or 12 hours before the next dose of the PPI/PCAB. Closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Infigratinib. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Itraconazole. This specifically applies to the super bioavailable itraconazole products (eg, Tolsura brand). Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Itraconazole. This specifically applies to the non-super bioavailable itraconazole products (eg, Sporanox brand and its generics).  Management: Exposure to Tolsura brand itraconazole may be increased by PPIs or PCABs ; consider itraconazole dose reduction. Exposure to Sporanox brand itraconazole may be decreased. Give Sporanox brand itraconazole at least 2 hrs before or 2 hrs after PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).  Management: Administer ketoconazole with an acidic beverage, such as non-diet cola, to increase gastric acidity and improve absorption if concomitant use with proton pump inhibitors or potassium-competitive acid blockers is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Ledipasvir.  Management: PPI  or PCAB doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Use of ledipasvir with higher doses or with food, or 2 hours after a these agents, may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Levoketoconazole. Levoketoconazole may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Methotrexate.  Management: Consider temporarily interrupting PPI or PCAB therapy in patients receiving high-dose methotrexate. If coadministered, monitor for increased methotrexate toxicity (eg, mucositis, myalgias) and/or delayed methotrexate elimination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nelfinavir.  Management: Due to potentially significant reductions in nelfinavir exposure, avoid concurrent use of nelfinavir with a PPI or PCAB when possible. If unavoidable, consider PPI or PCAB use for a short duration (less than 30 days) and closely monitor viral load.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nilotinib.  Management: Avoid this combination. Histamine H2 receptor antagonists (H2RAs) given 10 hours before or 2 hours after nilotinib, or antacids given 2 hours before or 2 hours after nilotinib are acceptable alternatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Palbociclib. Specifically, this has been reported with the use of palbociclib capsules. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Palbociclib. Specifically, this may occur with the use of palbociclib capsules, and to the greatest extent when taken without food.  Management: Carefully evaluate potential risks and benefits of coadministration of palbociclib capsules and proton pump inhibitors or potassium-competitive acid blockers due to the risk of reduced palbociclib efficacy. Palbociclib capsules should be taken with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Pexidartinib.  Management: Avoid this combination. If acid-reduction is needed, consider administering an antacid 2 hours before or after pexidartinib, or administer pexidartinib 2 hours before or 10 hours after an H2 receptor antagonist.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Posaconazole.  Management: Avoid coadministration of PPIs or PCABs and posaconazole oral suspension. Posaconazole delayed-release tablets do not appear to be sensitive to this interaction and do not required dose adjustment if coadministered with PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Risedronate. Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.  Management: Coadministration of PPIs or PCABs with delayed-release risedronate formulations is not recommended. Limit PPI/PCAB dose and duration during coadministration with risedronate as possible. Patients over age 70 are at higher risk of adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of PPIs or PCABs and secretin, and discontinue PPI or PCAB several weeks prior to secretin administration, with the duration of separation determined by the specific acid suppressant. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and PPIs or PCABs should be avoided. If coadministration cannot be avoided, selpercatinib and PPIs or PCABs should be administered simultaneously with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Dexlansoprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Sestamibi: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Sestamibi.  Management: Consider holding/stopping proton pump inhibitor therapy for at least 3 days prior to the use technetium Tc 99m sestamibi in cardiac imaging procedures.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tetrofosmin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Tetrofosmin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Inhibitors of the Proton Pump (PPIs and PCABs) may enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Velpatasvir.  Management: Sofosbuvir/velpatasvir should be administered with food and taken 4 hours before omeprazole 20 mg. Sofosbuvir/velpatasvir/voxilaprevir can be administered with omeprazole 20 mg. Use with other PPIs or PCABs has not been studied.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Dexlansoprazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F24788517"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>
<div class="block pri drugH1Div" id="F6892894"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following use of proton pump inhibitors (PPIs) during pregnancy are available (Choi 2023; Hussain 2022; Peron 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for the treatment of gastroesophageal reflux disease in pregnant patients are available. When initiating treatment during pregnancy, a step-up approach, starting with diet and lifestyle modifications, is recommended. PPIs are considered acceptable for use during pregnancy when other medications are not effective (Ali 2022; Dunbar 2022; Thélin 2020).</p></div>
<div class="block brc drugH1Div" id="F20233464"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dexlansoprazole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F46944482"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Magnesium (baseline and periodically thereafter; especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia) and calcium (baseline and periodically in patients at risk [eg, hypoparathyroidism]).</p></div>
<div class="block pha drugH1Div" id="F6892943"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Proton pump inhibitor; decreases acid secretion in gastric parietal cells through inhibition of (H+, K+)-ATPase enzyme system, blocking the final step in gastric acid production</p></div>
<div class="block phk drugH1Div" id="F6892945"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Symptomatic GERD: 40 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 96% to 99%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (extensive) via CYP2C19-mediated hydroxylation and CYP3A4-mediated oxidation; followed by reduction to sulfate, glucuronide, and glutathione conjugates (inactive)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: May be increased when administered with food</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: ~1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Two distinct peaks secondary to dual release formulation: Initial peak between 1 and 2 hours and a second higher peak between 4 and 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~51% as metabolites); feces (~48%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> CYP2C19 polymorphism is expected to affect dexlansoprazole exposure. In a study involving Japanese men following a single dose of dexlansoprazole, C<sub>max</sub> and AUC were up to 2 times greater in intermediate metabolizers compared to extensive metabolizers. In addition, mean C<sub>max</sub> and mean AUC were up to 4 times greater and up to 12 times greater, respectively, in poor metabolizers compared to extensive metabolizers.</p></div>
<div class="block phksp drugH1Div" id="F51220997"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma exposure to the drug is ~2 times greater in patients with moderate hepatic impairment (Child-Pugh class B) compared with subjects with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Systemic exposures in children and adolescents 12 to 17 years of age were similar to those observed in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The elimination half-life is increased and AUC is higher in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Systemic exposure is 43% higher in females than in males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059481"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Apatrix | Arigastril | Dexopral | Ibepral</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Delanix | Dexila | Dexilend | Dexoprex | Dlp</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dexlansoprazol | Dexlanzopral | Dexopral</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dexlansoprazol ethical | Dexlanzopral</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dexilant | Dexlanzopral</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dexilant | Doxirazol | Lantopep | Protolans | Ulcezole</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Deltone</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gladexa</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dolgina</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dexirazole</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dexivant</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dexilant | Dexlanzopral</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Daplazole | Ddr | Delanzo | Dexiva | Dextol | Dolgina | Dudex | Dxl | Kapdex | Kewdex | Redexa | Remit dr | Stomdex | Werdex | Wilsop | Xanilo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dexilant</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26621819">
<a name="26621819"></a>Abdul-Hussein M, Freeman J, Castell D. Concomitant administration of a histamine2 receptor antagonist and proton pump inhibitor enhances gastric acid suppression. <i>Pharmacotherapy</i>. 2015;35(12):1124-1129. doi:10.1002/phar.1665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/26621819/pubmed" id="26621819" target="_blank">26621819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation</i>. 2010;122(24):2619-2633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35508989">
<a name="35508989"></a>Ali RAR, Hassan J, Egan LJ. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. <i>BMC Gastroenterol</i>. 2022;22(1):219. doi:10.1186/s12876-022-02287-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/35508989/pubmed" id="35508989" target="_blank">35508989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21640290">
<a name="21640290"></a>Bell AD, Roussin A, Cartier R, et al. The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Can J Cardiol</i>. 2011;27(suppl A):1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/21640290/pubmed" id="21640290" target="_blank">21640290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bonis.1">
<a name="Bonis.1"></a>Bonis PAL, Gupta SK. Treatment of eosinophilic esophagitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36626173">
<a name="36626173"></a>Choi A, Noh Y, Jeong HE, et al. Association between proton pump inhibitor use during early pregnancy and risk of congenital malformations. <i>JAMA Netw Open</i>. 2023;6(1):e2250366. doi:10.1001/jamanetworkopen.2022.50366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/36626173/pubmed" id="36626173" target="_blank">36626173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23034135">
<a name="23034135"></a>de Jager CP, Wever PC, Gemen EF, et al, “Proton Pump Inhibitor Therapy Predisposes to Community-Acquired <i>Streptococcus pneumoniae</i> Pneumonia,” <i>Aliment Pharmacol Ther</i>, 2012, 36(10):941-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/23034135/pubmed" id="23034135" target="_blank">23034135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15654800">
<a name="15654800"></a>DeVault KR and Castell DO, “Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease,” <i>Am J Gastroenterol</i>, 2005, 100(1):190-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/15654800/pubmed" id="15654800" target="_blank">15654800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Takeda.1">
<a name="Takeda.1"></a>Dexilant (dexlansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Takeda.1">
<a name="Takeda.1"></a>Dexilant (dexlansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Takeda.1">
<a name="Takeda.1"></a>Dexilant (dexlansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26958557">
<a name="26958557"></a>DiGiovanni EL, Champeaux AL, Arroyo MR, Richter JE. Esophageal eosinophilia treated with long-duration proton pump inhibitor therapy. <i>ACG Case Rep J</i>. 2016;3(2):95-97. doi:10.14309/crj.2016.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/26958557/pubmed" id="26958557" target="_blank">26958557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36194028">
<a name="36194028"></a>Dunbar K, Yadlapati R, Konda V. Heartburn, nausea, and vomiting during pregnancy. <i>Am J Gastroenterol</i>. 2022;117(10S):10-15. doi:10.14309/ajg.0000000000001958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/36194028/pubmed" id="36194028" target="_blank">36194028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9468251">
<a name="9468251"></a>Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. <i>Am J Gastroenterol</i>. 1998;93(2):238-243. doi:10.1111/j.1572-0241.1998.00238.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/9468251/pubmed" id="9468251" target="_blank">9468251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102658">
<a name="27102658"></a>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/27102658/pubmed" id="27102658" target="_blank">27102658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17505990">
<a name="17505990"></a>Fändriks L, Lönroth H, Pettersson A, Vakil N. Can famotidine and omeprazole be combined on a once-daily basis? <i>Scand J Gastroenterol</i>. 2007;42(6):689-694. doi:10.1080/00365520601026665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/17505990/pubmed" id="17505990" target="_blank">17505990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fass.2019">
<a name="Fass.2019"></a>Fass R. Approach to refractory gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19392864">
<a name="19392864"></a>Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. <i>Aliment Pharmacol Ther</i>. 2009;29(12):1261-1272. doi:10.1111/j.1365-2036.2009.04013.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/19392864/pubmed" id="19392864" target="_blank">19392864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22464259">
<a name="22464259"></a>Frelinger AL 3rd, Lee RD, Mulford DJ, et al, “A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,” <i>J Am Coll Cardiol</i>, 2012, 59(14):1304-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/22464259/pubmed" id="22464259" target="_blank">22464259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25192903">
<a name="25192903"></a>Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. <i>Fam Pract</i>. 2014;31(6):625-630. doi:10.1093/fampra/cmu050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/25192903/pubmed" id="25192903" target="_blank">25192903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32359562">
<a name="32359562"></a>Hirano I, Chan ES, Rank MA, et al; AGA Institute Clinical Guidelines Committee; Joint Task Force on Allergy-Immunology Practice Parameters. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. <i>Gastroenterology</i>. 2020;158(6):1776-1786. doi:10.1053/j.gastro.2020.02.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/32359562/pubmed" id="32359562" target="_blank">32359562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36012913">
<a name="36012913"></a>Hussain S, Singh A, Antony B, et al. Proton pump inhibitors use and risk of preeclampsia: a meta- analysis. <i>J Clin Med</i>. 2022;11(16):4675. doi:10.3390/jcm11164675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/36012913/pubmed" id="36012913" target="_blank">36012913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kahrilas.2021">
<a name="Kahrilas.2021"></a>Kahrilas PJ. Medical management of gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18789939">
<a name="18789939"></a>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. <i>Gastroenterology</i>. 2008;135(4):1383-1391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/18789939/pubmed" id="18789939" target="_blank">18789939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34807007">
<a name="34807007"></a>Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/34807007/pubmed" id="34807007" target="_blank">34807007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26228516">
<a name="26228516"></a>Kavitt RT, Ates F, Slaughter JC, et al. Randomized controlled trial comparing esophageal dilation to no dilation among adults with esophageal eosinophilia and dysphagia. <i>Dis Esophagus</i>. 2016;29(8):983-991. doi:10.1111/dote.12398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/26228516/pubmed" id="26228516" target="_blank">26228516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767318">
<a name="29767318"></a>Kim J, Blackett JW, Jodorkovsky D. Strategies for effective discontinuation of proton pump inhibitors. <i>Curr Gastroenterol Rep</i>. 2018;20(6):27. doi:10.1007/s11894-018-0632-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/29767318/pubmed" id="29767318" target="_blank">29767318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19240698">
<a name="19240698"></a>Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. <i>Am J Gastroenterol</i>. 2009;140(3):728-738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/19240698/pubmed" id="19240698" target="_blank">19240698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32677040">
<a name="32677040"></a>Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al; EUREOS EoE CONNECT research group. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. <i>Aliment Pharmacol Ther</i>. 2020;52(5):798-807. doi:10.1111/apt.15957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/32677040/pubmed" id="32677040" target="_blank">32677040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26752337">
<a name="26752337"></a>Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. <i>JAMA Intern Med</i>. 2016;238-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/26752337/pubmed" id="26752337" target="_blank">26752337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i>. 2011;124(23):e574-e651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15258107">
<a name="15258107"></a>Li XQ, Andersson TB, Ahalström M, et al. Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole and Rabeprazole on Human Cytochrome P450 Activities. <i>Drug Metab Dispo</i>. 2004;32(8):821-827.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/15258107/pubmed" id="15258107" target="_blank">15258107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26247167">
<a name="26247167"></a>Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2016;14(1):13-22.e1. doi:10.1016/j.cgh.2015.07.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/26247167/pubmed" id="26247167" target="_blank">26247167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31175146">
<a name="31175146"></a>Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. <i>Pediatrics</i>. 2019;144(1):e20182625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/31175146/pubmed" id="31175146" target="_blank">31175146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25112692">
<a name="25112692"></a>Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. <i>J Pediatr</i>. 2014;165(5):979-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/25112692/pubmed" id="25112692" target="_blank">25112692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21795468">
<a name="21795468"></a>Ogilvie BW, Yerino P, Kazmi F, et al. The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel. <i>Drug Metab Dispos</i>. 2011;39(11):2020-2033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/21795468/pubmed" id="21795468" target="_blank">21795468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37269915">
<a name="37269915"></a>Peron A, Ripoche E, Picot C, Ajiji P, Cucherat M, Cottin J. Use of proton pump inhibitors during pregnancy: a systematic review and meta-analysis of congenital malformations. <i>Reprod Toxicol</i>. 2023;119:108419. doi:10.1016/j.reprotox.2023.108419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/37269915/pubmed" id="37269915" target="_blank">37269915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26939578">
<a name="26939578"></a>Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. <i>Aliment Pharmacol Ther</i>. 2016;43(9):985-993. doi:10.1111/apt.13576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/26939578/pubmed" id="26939578" target="_blank">26939578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35354777">
<a name="35354777"></a>Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. <i>Am J Gastroenterol</i>. 2022;117(4):559-587. doi:10.14309/ajg.0000000000001680<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/35354777/pubmed" id="35354777" target="_blank">35354777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19183157">
<a name="19183157"></a>Sharma P, Shaheen NJ, Perez MC, et al, “Healing of Erosive Oesophagitis With TAK-390MR, a Proton Pump Inhibitor With a Novel Dual Delayed-Release Formulation: Results From Two Randomized Controlled Studies,” <i>Aliment Pharmacol Ther</i>, 2009, 29(7):731-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/19183157/pubmed" id="19183157" target="_blank">19183157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23350044">
<a name="23350044"></a>Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. <i>J Neurogastroenterol Motil</i>. 2013;19(1):25-35. doi:10.5056/jnm.2013.19.1.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/23350044/pubmed" id="23350044" target="_blank">23350044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17112810">
<a name="17112810"></a>Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. <i>Clin Pharmacol Ther</i>. 2006;80(5):539-548. doi:10.1016/j.clpt.2006.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/17112810/pubmed" id="17112810" target="_blank">17112810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16181387">
<a name="16181387"></a>Talley NJ and Vakil N, “Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,” <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/16181387/pubmed" id="16181387" target="_blank">16181387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32691466">
<a name="32691466"></a>Talley NJ, Zand Irani M. Optimal management of severe symptomatic gastroesophageal reflux disease. <i>J Intern Med</i>. 2021;289(2):162-178. doi:10.1111/joim.13148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/32691466/pubmed" id="32691466" target="_blank">32691466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35183361">
<a name="35183361"></a>Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. <i>Gastroenterology</i>. 2022;162(4):1334-1342. doi:10.1053/j.gastro.2021.12.247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/35183361/pubmed" id="35183361" target="_blank">35183361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31950535">
<a name="31950535"></a>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. <i>Aliment Pharmacol Ther</i>. 2020;51(4):421-434. doi:10.1111/apt.15611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/31950535/pubmed" id="31950535" target="_blank">31950535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047577">
<a name="20047577"></a>Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. <i>Aliment Pharmacol Ther</i>. 2010;31(7):754-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/20047577/pubmed" id="20047577" target="_blank">20047577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117619">
<a name="24117619"></a>Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, Devault KR, Talley NJ, Achem SR. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. <i>Aliment Pharmacol Ther</i>. 2013;38(10):1312-1319. doi:10.1111/apt.12513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/24117619/pubmed" id="24117619" target="_blank">24117619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19821323">
<a name="19821323"></a>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. <i>Cochrane Database Syst Rev</i>. 2009;(4):CD004275. doi:10.1002/14651858.CD004275.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/19821323/pubmed" id="19821323" target="_blank">19821323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176276">
<a name="32176276"></a>Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association between proton pump inhibitor use and risk of fracture in children. <i>JAMA Pediatr</i>. 2020;174(6):543-551. doi:10.1001/jamapediatrics.2020.0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/32176276/pubmed" id="32176276" target="_blank">32176276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10868896">
<a name="10868896"></a>Wolfe MM and Sachs G, “Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,” <i>Gastroenterology</i>, 2000,118(2 Suppl 1):9-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/10868896/pubmed" id="10868896" target="_blank">10868896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wolfe.1">
<a name="Wolfe.1"></a>Wolfe MM. Proton pump inhibitors: overview of use and adverse effects in the treatment of acid related disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31597230">
<a name="31597230"></a>Wu JCY, Sheu BS, Wu MS, Lee YC, Choi MG. Phase 4 study in patients from Asia with gastroesophageal reflux disease treated with dexlansoprazole. <i>J Neurogastroenterol Motil</i>. 2020;26(1):85-95. doi:10.5056/jnm19031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/31597230/pubmed" id="31597230" target="_blank">31597230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19248200">
<a name="19248200"></a>Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. <i>World J Gastroenterol</i>. 2009;15(8):990-995. doi:10.3748/wjg.15.990<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexlansoprazole-drug-information/abstract-text/19248200/pubmed" id="19248200" target="_blank">19248200</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9074 Version 351.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
